C. Chouaïd

17.9k total citations · 1 hit paper
500 papers, 7.2k citations indexed

About

C. Chouaïd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, C. Chouaïd has authored 500 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 325 papers in Pulmonary and Respiratory Medicine, 256 papers in Oncology and 81 papers in Epidemiology. Recurrent topics in C. Chouaïd's work include Lung Cancer Treatments and Mutations (237 papers), Lung Cancer Diagnosis and Treatment (114 papers) and Cancer Immunotherapy and Biomarkers (87 papers). C. Chouaïd is often cited by papers focused on Lung Cancer Treatments and Mutations (237 papers), Lung Cancer Diagnosis and Treatment (114 papers) and Cancer Immunotherapy and Biomarkers (87 papers). C. Chouaïd collaborates with scholars based in France, United States and Germany. C. Chouaïd's co-authors include A. Vergnenègre, I. Monnet, Gilles Hejblum, Olivier Bylicki, Fabrice Barlési, Marie Wislez, Serge Adnot, Jean‐Baptiste Assié, Florian Guisier and Bernard Maître and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

C. Chouaïd

455 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

2013 489 citations Julien Mazières, Alexis B. Cortot et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by C. Chouaïd

Since Specialization

Citations

This map shows the geographic impact of C. Chouaïd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Chouaïd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Chouaïd more than expected).

Fields of papers citing papers by C. Chouaïd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Chouaïd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Chouaïd. The network helps show where C. Chouaïd may publish in the future.

Co-authorship network of co-authors of C. Chouaïd

This figure shows the co-authorship network connecting the top 25 collaborators of C. Chouaïd. A scholar is included among the top collaborators of C. Chouaïd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Chouaïd. C. Chouaïd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis 2025 ·Frontiers in Oncology ·(unknown), C. Chouaïd, D. Debieuvre, Clarisse Audigier-Valette, Xavier Quantin, H. Léna, L. Bosquet, Nicolas Girard, Minouk J. Schoemaker, (unknown), Bruno E. Correia, (unknown), M. Daumont, John R. Penrod, Adam Lee, (unknown)	1
2	Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study 2025 ·Lung Cancer ·(unknown), Laurent Greillier, Florian Guisier, Catherine Daniel, R. Descourt, Loïck Galland, Olivier Molinier, C. Decroisette, Alexis B. Cortot, (unknown), Laurence Gamé, Marie Wislez, Nicolas Cloarec, (unknown), (unknown), J. Cadranel, Boris Duchemann, (unknown), C. Chouaïd, J.B. Auliac	0
3	Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study 2025 ·Lung Cancer ·C. Chouaïd, L. Bosquet, Craig Knott, (unknown), (unknown), Xiwu Lin, (unknown), (unknown), Joris Diels, Esther Caparrós, Francesca Galea, Agnes Hultén, Alastair Greystoke	0
4	The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and Germany 2024 ·Journal of Medical Economics ·C. Chouaïd, (unknown), (unknown), Björn Stollenwerk, Farastuk Bozorgmehr	2
5	ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. 2024 ·Journal of Clinical Oncology ·David Planchard, Nathalie Cozic, Marie Wislez, C. Chouaïd, (unknown), Sophie Cousin, Céline Mascaux, Jacques Cadranel, Margaux Geier, Maria‐Rosa Ghigna, (unknown), Ricardo Zwirtes, Rachel Chiaverelli, (unknown), (unknown), Fernanda Mosele, Fabrice André, Guillaume Montagnac, Barbara Pistilli	6
6	Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis 2024 ·ESMO Open ·Thierry Landré, Abdoulaye Karaboué, Zachary S. Buchwald, Pasquale F. Innominato, David C. Qian, Jean‐Baptiste Assié, C. Chouaïd, Françis Lévi, Boris Duchemann	32
7	Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy 2023 ·Respiratory Medicine and Research ·Clarisse Audigier-Valette, Thomas Filleron, D. Debieuvre, H. Léna, M. Pérol, C. Chouaïd, (unknown), Xavier Quantin, Nicolas Girard	5
8	PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors 2023 ·Respiratory Medicine and Research ·(unknown), Vincent Fallet, Boris Duchemann, Stéphane Jouveshomme, J. Cadranel, C. Chouaïd	5
9	2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study 2023 ·Annals of Oncology ·E. Sebbag, Nicolas Cloarec, I. Monnet, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), C. Chouaïd, (unknown), (unknown)	1
10	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo) 2023 ·Lung Cancer ·A. Vergnenègre, I. Monnet, Charles Ricordel, (unknown), (unknown), Massimo Bernardi, R. Corre, Florian Guisier, S. Hominal, G. Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, C. Chouaïd, G. Robinet	5
11	Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors 2023 ·Lung Cancer ·Pierre-Étienne Heudel, Anne Montfort, D. Debieuvre, C. Chouaïd, Matthieu Carton, Clarisse Audigier-Valette, Thomas Filleron, Sylvie Chabaud, (unknown), Xavier Quantin, Sandrine Hiret, L. Bosquet, Jean‐Yves Blay	0
12	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study 2022 ·Cancers ·R. Descourt, M. Pérol, (unknown), David Planchard, B. Mennecier, Marie Wislez, Jacques Cadranel, Alexis B. Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schött, Éric Dansin, Jennifer Arrondeau, J.B. Auliac, Margaux Geier, C. Chouaïd	5
13	Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab 2022 ·JCO Clinical Cancer Informatics ·C. Chouaïd, (unknown), (unknown), R. Corre, Matteo Giaj Levra, Anne-Françoise Gaudin, (unknown), Joannie Lortet‐Tieulent, Jean‐Baptiste Assié, François-Emery Cotté	6
14	Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts 2022 ·Cancers ·C. Chouaïd, Michael Thomas, D. Debieuvre, Isabelle Durand‐Zaleski, Stefan Zacharias, L. Bosquet, (unknown), (unknown), Alan Calleja, (unknown), (unknown), M. Daumont, John R. Penrod, Robert Carroll, (unknown), François-Emery Cotté, Clarisse Audigier-Valette, Frank Griesinger	3
15	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients 2021 ·Cancers ·V. Gounant, M. Duruisseaux, (unknown), (unknown), Olivier Bylicki, Jacques Cadranel, Marie Wislez, Jean Trédaniel, Jean‐Philippe Spano, Carole Hélissey, C. Chouaïd, Olivier Molinier, X. Dhalluin, Ludovic Doucet, J. Hureaux, Aurélie Cazes, Gérard Zalcman	9
16	A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer 2015 ·Lung Cancer ·Gerald Schmid‐Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, (unknown), Jürgen R. Fischer, Julien Mazières, C. Chouaïd, M. Wolf, Núria Viñolas, Victoria Soldatenkova, Veronique Ripoche, Tuan S. Nguyen, Carla Visseren‐Grul	9
17	Cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the preoperative staging of lung cancer, results from the French prospective multicenter trial "EVIEPEB" 2013 ·European Respiratory Journal ·Mathieu Salaün, C. Chouaïd, V. Gounant, M. Febvre, Jean‐Michel Vergnon, V. Jounieaux, C. Fournier, Samy Lachkar, C. Hermant, (unknown), Xavier Quantin, (unknown), (unknown), C. Dayen, Charles‐Hugo Marquette, H. Léna, Gérard Zalcman, Nicolas Favrolt, Luc Thiberville	0
18	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166
19	Pulmonary Artery Smooth Muscle Cell Senescence Is a Pathogenic Mechanism for Pulmonary Hypertension in Chronic Lung Disease 2011 ·Circulation Research ·(unknown), Guillaume Gary‐Bobo, Marco Alifano, Élisabeth Marcos, Mirna Saker, N. Vienney, Valérie Amsellem, Bernard Maître, Ari Chaouat, C. Chouaïd, Jean‐Luc Dubois‐Randé, Diane Damotte, Serge Adnot	114
20	[Demography of lung specialists in France]. 2003 ·PubMed ·C. Chouaïd, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact